<DOC>
	<DOCNO>NCT00686374</DOCNO>
	<brief_summary>Efficacy Long Term Safety Adalimumab Pediatric Subjects Who Have Demonstrated Clinical Response M06-806 .</brief_summary>
	<brief_title>Efficacy Long Term Safety Adalimumab Pediatric Subjects Who Have Demonstrated Clinical Response M06-806</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject must successfully enrol complete Protocol M06806 Week 52 . Subject must responder time point M06806 study . If female , subject sexually active childbearing potential practicing approve method birth control throughout study 150 day study drug administration . Examples approve method birth control include follow : 1 . Condoms , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) 2 . Oral , parenteral intravaginal contraceptive 3 . A vasectomized partner Subject legal age , parent legal guardian , require , voluntarily sign date Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve informed consent form , nature study explain subject legal age , subject 's parent , legal guardian , require , opportunity ask question . Subjects include discussion , require , signature assent form obtain . Parent legal guardian subject legal age , require , must willing actively supervise storage administration study drug ensure time dose accurately record subject 's diary . If subject legal age , must willing actively store , administer , accurately record study drug administration subject diary . Subject judge acceptable medical condition , determine Principal Investigator base upon result clinical laboratory evaluation do throughout precede Crohn 's disease study M06806 . For reason , subject consider Investigator unsuitable candidate continue therapy M06807 study . Subject abnormal laboratory test result opinion Investigator make subject unsuitable participate study . History cancer lymphoproliferative disease successfully completely treat cutaneous squamous cell basal cell carcinoma carcinoma âˆ’ insitu cervix . History listeriosis , histoplasmosis , chronic active hepatitis B infection , human immunodeficiency virus ( HIV ) infection , immunodeficiency syndrome , central nervous system ( CNS ) demyelinate disease active TB ( receive treatment receive treatment ) . Ongoing severe infection sepsis opportunistic infection exclusionary . Subject know , symptomatic obstructive stricture . Subject plan surgical bowel resection time point enrol study . Subject short bowel syndrome determine Investigator . Subject currently receive total parenteral nutrition ( TPN ) . Subject unwilling discontinue growth hormone prior first dose openlabel study drug Baseline visit M06807 . Female subject pregnant currently breastfeed . Subject history clinically significant drug alcohol abuse last year . Subject poorly control medical condition : uncontrolled diabetes , recurrent infection , unstable ischemic heart disease , moderate severe heart failure , recent cerebrovascular accident condition , opinion Investigator Sponsor , put subject risk participation protocol . Subject prior exposure Tysabri ( natalizumab ) . Subject know hypersensitivity excipients adalimumab state label . Subject previous history dysplasia gastrointestinal tract .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>adalimumab</keyword>
</DOC>